Pfizer (PFE) Cash from Investing Activities (2009 - 2026)

Pfizer (PFE) has reported Cash from Investing Activities for 18 consecutive years, with $785.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 76.02% year-over-year to $785.0 million; the TTM figure through Mar 2026 stood at -$3.8 billion (down 127.66% YoY), while the FY2025 annual figure was -$1.4 billion, down 150.94% from the prior year.
• Cash from Investing Activities grew to $785.0 million in Q1 2026 per PFE's latest filing, from -$6.1 billion in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $4.6 billion in Q2 2024 and bottomed at -$25.5 billion in Q3 2023.
• Historically, Cash from Investing Activities has averaged -$2.6 billion across 5 years, with a median of $785.0 million in 2026.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities surged 484.66% — and 2025, when it slumped 156.84%.
• Pfizer's Cash from Investing Activities stood at -$11.3 billion in 2022, then advanced by 2.8% to -$11.0 billion in 2023, then soared by 138.88% to $4.3 billion in 2024, then tumbled by 243.77% to -$6.1 billion in 2025, then jumped by 112.77% to $785.0 million in 2026.
• Business Quant data shows PFE's Cash from Investing Activities at $785.0 million in Q1 2026, -$6.1 billion in Q4 2025, and -$2.4 billion in Q3 2025.